THERAPY SYSTEMS INCLUDING HYPERTHERMIC ENERGY DELIVERY ELEMENTS AND CRYOGENIC APPLICATORS AND ASSOCIATED METHODS

• US 20130289678A1
• Filed: 04/27/2012
• Published: 10/31/2013
• Est. Priority Date: 04/27/2012
• Status: Abandoned Application

• Current Assignee: Medtronic Ardian Luxembourg SARL (Medtronic Plc)
• Original Assignee: Medtronic Ardian Luxembourg SARL (Medtronic Plc)
• Inventors: Clark, Benjamin J., Condie, Catherine, Francishelli, David
• Application Number:
  US13/458,859
• Publication Number:
  US 20130289678A1
• Time in Patent Office: Days
• US Class Current: 607/101
• CPC Class Codes: A61B 18/02 by cooling, e.g. cryogenic techniques devices for cooling specific reflex points of the body within cell-life limits A61H39/06
• CPC Class Codes: A61B 18/1492 having a flexible, catheter-like structure, e.g. for heart ablation A61B18/1477 takes precedence
• CPC Class Codes: A61B 18/24 with a catheter A61B18/26, A61B18/28 take precedence
• CPC Class Codes: A61B 2018/00404 Blood vessels other than those in or around the heart
• CPC Class Codes: A61B 2018/00434 Neural system
• CPC Class Codes: A61B 2018/00511 Kidney
• CPC Class Codes: A61B 2018/00577 Ablation
• CPC Class Codes: A61B 2018/0212 using an instrument inserted into a body lumen, e.g. catheter
• CPC Class Codes: A61B 2018/1435 Spiral
• CPC Class Codes: A61B 2018/1861 with an instrument inserted into a body lumen or cavity, e.g. a catheter

Abstract

Therapy systems for hyperthermic energy delivery and cryogenic cooling and associated methods of use. A treatment device can have a distal portion with a therapeutic assembly including an energy delivery element and a cryogenic applicator. The energy delivery element can be configured to apply therapeutically-effective hyperthermic energy to a treatment site (e.g., for neuromodulation). The cryogenic applicator can be configured to cool tissue at least proximate the treatment site.

Claims

1. A treatment device, comprising:

a shaft including a proximal portion and a distal portion, wherein the shaft is configured to insert the distal portion at a treatment site at least proximate a renal artery;

a therapeutic assembly extending from the distal portion of the shaft, the therapeutic assembly comprising—

an energy delivery element configured to apply therapeutically-effective hyperthermic energy to tissue at the treatment site to modulate renal nerves proximate the treatment site; and

a cryogenic applicator configured to cool tissue at least proximate the treatment site.

2. The treatment device of claim 1 wherein:

the therapeutic assembly has a delivery state and a deployed state;

the energy delivery element comprises a plurality of energy delivery elements including at least a first electrode and a second electrode, wherein the first and second electrodes are configured to deliver therapeutically-effective radiofrequency energy to the treatment site when the therapeutic assembly is in the deployed state;

the cryogenic applicator includes an expandable member having an outer surface, the first and second electrodes being arranged about the outer surface, wherein the expandable member is configured to cool a zone at least proximate the treatment site when the therapeutic assembly is in the deployed state; and

the treatment device further comprises—

a supply lumen extending along at least a portion of the shaft, the supply lumen being configured to receive a refrigerant in an at least substantially liquid state, and

an exhaust lumen extending along at least a portion of the shaft and in fluid communication with the expandable member.

3. The treatment device of claim 1 wherein:

the energy delivery element comprises a plurality of energy delivery elements including at least a first electrode and a second electrode, wherein the first and second electrodes are configured to apply therapeutically-effective radiofrequency energy to the treatment site; and

the cryogenic applicator comprises a cryoprobe having a surface configured to cool a zone at least proximate the treatment site, wherein the first and second electrodes are spaced laterally apart from one another at opposing sides of the surface.

4. The treatment device of claim 1 wherein:

the cryogenic applicator comprises a cryoprobe;

the energy delivery element comprises a plurality of electrodes configured to deliver therapeutically-effective radiofrequency energy to the treatment site; and

the plurality of electrodes include at least a first electrode and a second electrode spaced laterally apart from one another with the cryogenic applicator between the first and second electrodes.

5. The treatment device of claim 1, further comprising a controller operably coupled to the cryogenic applicator and the energy delivery element, wherein the controller is configured to cool the treatment site via the cryogenic applicator before applying hyperthermic energy to the treatment site.

6. The treatment device of claim 5 wherein the cryogenic applicator is configured to cool the treatment site to decrease an impedance of the tissue at the treatment site.

7. The treatment device of claim 5 wherein the cryogenic applicator is configured to cool the treatment site to modulate pain neurons at the treatment site.

8. The treatment device of claim 1 wherein:

the therapeutic assembly has a delivery state and a deployed state; and

the energy delivery element comprises a plurality of electrodes arranged in a helical pattern when the therapeutic assembly is in the deployed state.

9. A treatment device, comprising:

a shaft including a proximal portion and a distal portion, wherein the shaft is configured to insert the distal portion at a treatment site at least proximate a renal artery;

an energy delivery element attached to the distal portion of the shaft and configured to deliver therapeutically-effective energy that modulates nerves that innervate the kidney, wherein the energy delivery element is configured to be operably coupled to a hyperthermic energy source positioned at the proximal portion of the shaft; and

a cryogenic applicator attached to the distal portion of the shaft and in fluid communication with a refrigerant source positioned at the proximal portion of the shaft.

10. The treatment device of claim 9 wherein the shaft, the energy delivery element, and the cryogenic applicator are sized to fit slideably within a guide catheter having a lumen diameter of approximately 1.80 mm (0.071 inch).

11. The treatment device of claim 9 wherein the expandable member is configured to at least substantially occlude the renal artery in the deployed state.

12. The treatment device of claim 9 wherein the cryogenic applicator comprises a cryoprobe having an applicator surface configured to cool a zone, and wherein the energy delivery element is spaced laterally apart from the zone.

13. The treatment device of claim 9 wherein the cryogenic applicator is configured to cool the energy delivery element during delivery of hyperthermic energy.

14. The treatment device of claim 9 wherein the cryogenic applicator is configured to cool the treatment site before delivery of hyperthermic energy.

15. A method of treating a patient, comprising:

inserting a therapeutic assembly to a treatment site in a renal artery, wherein the therapeutic assembly extends from a distal portion of an elongated shaft;

cooling a zone at least proximate the treatment site using a cryogenic applicator of the therapeutic assembly; and

applying therapeutically-effective hyperthermic energy to the treatment site to cause renal nerve modulation using an energy delivery element of the therapeutic assembly.

16. The method of claim 15 wherein cooling the zone at least proximate the treatment site comprises cooling tissue at least proximate the zone for a time interval before applying the therapeutically-effective hyperthermic energy to the treatment site.

17. The method of claim 15 wherein cooling the zone at least proximate the treatment site comprises cooling tissue at the zone for at least 1 minute at a temperature of less than 0°

C. before applying the therapeutically-effective hyperthermic energy to the renal nerves.

18. The method of claim 15 wherein cooling the zone comprises:

cooling the zone for a first time interval having a duration of at least 1 minute;

thawing the zone for a second time interval having a duration of at least 1 minute; and

cooling the zone of tissue for a second time interval having a duration of at least 1 minute, wherein cooling and thawing occur before applying the therapeutically-effective hyperthermic energy at the treatment site.

19. The method of claim 15 wherein the energy delivery element is a first energy delivery element, and wherein cooling the zone comprises:

freezing a portion of tissue in the zone to the cryogenic applicator before applying the therapeutically-effective hyperthermic energy at the treatment site; and

applying a low-level of energy across the portion of tissue using the first energy delivery element and a second energy delivery element, the first energy delivery element being spaced laterally apart from the second energy delivery element by the portion of tissue, wherein the application of low-level energy is configured to prevent freezing the tissue at the first and second energy delivery elements.

20. The method of claim 15 wherein cooling the zone comprises freezing pain neurons at least proximate the target site, and wherein cooling occurs before the application of hyperthermic energy.

21. The method of claim 15 wherein cooling the zone at least proximate the treatment site comprises decreasing the impedance characteristics of the tissue at the treatment site, wherein cooling occurs before the application of hyperthermic energy.

22. The method of claim 15 wherein cooling the zone at least proximate the treatment site comprises:

positioning the cryogenic applicator on a protected portion of tissue proximate the treatment site; and

cooling the protected portion of tissue during the application of hyperthermic energy.

23. The method of claim 22 wherein cooling the protected portion comprises maintaining a tissue temperature between about 5°

C. and about 35°

C. at the protected portion during the application of hyperthermic energy.

24. The method of claim 25 wherein cooling the zone at least proximate the treatment site comprises:

cooling the treatment site using the cryogenic applicator before applying hyperthermic energy;

measuring impedance at the treatment site resulting from the cooling; and

applying additional cooling to the treatment site using the cryogenic applicator when the treatment site has a measured impedance above a predetermined threshold, wherein the cooling and measuring steps are repeated until an impedance is measured below the predetermined threshold.

25. The method of claim 15 wherein:

locating the therapeutic assembly at the treatment site comprises locating a first energy delivery element at a first portion of the treatment site, and locating a second energy delivery element at a second portion of the treatment site spaced apart from the first portion;

cooling the zone comprises cooling the first energy delivery element to approximately 5-35°

C. during the application of hyperthermic energy by the first energy delivery element, and cooling the second energy delivery element to below 0°

C.; and

applying therapeutically-effective hyperthermic energy at the treatment site comprises applying hyperthermic energy at the treatment site using only the first energy delivery element.

26. The method of claim 15 wherein:

cooling the zone comprises freezing a portion of the cryogenic applicator to tissue at least proximate the treatment site to form a temporary bond between the therapeutic assembly and the cryogenic applicator; and

the method further comprises applying hyperthermic energy to the temporary bond after renal nerve modulation to thaw the bond.

27. A method of treating a patient, comprising:

locating a therapeutic assembly at a treatment site at least proximate a renal artery, wherein the therapeutic assembly is at a distal portion of an elongated shaft;

applying therapeutically-effective cryogenic cooling at the treatment site using a cryogenic applicator of the therapeutic assembly to modulate nerves that innervate the kidney;

freezing at least a portion of the cryogenic applicator to tissue at the treatment site to form a temporary frozen attachment; and

applying hyperthermic energy at least proximate the temporary frozen attachment using an energy delivery element of the therapeutic assembly to thaw the frozen attachment.